Table 2.

Results for new‐onset diabetes mellitus from the network meta‐analysis (lower diagonal part) and pairwise meta‐analysis (upper diagonal part)

Treatment	Placebo	ACEI	ARB	β‐Blocker	β‐Blocker+diuretic	CCB	Diuretic
Placebo	1	0.77 (0.61–0.97)	0.86 (0.81–0.91)	2.18 (1.36–3.50)	–	1.16 (1.05–1.29)	1.61 (0.95–2.72)
ACEI	1.22 (1.01–1.52)	1	–	1.25 (0.84–1.86)	1.12 (0.96–1.30)	1.23 (1.01–1.50)	1.36 (1.12–1.66)
ARB	1.30 (1.07–1.60)	1.07 (0.82–1.39)	1	1.37 (1.16–1.62)	–	1.27 (1.14–1.43)	1.90 (0.90–4.01)
β‐Blocker	0.83 (0.63–1.08)	0.68 (0.51–0.90)	0.64 (0.47–0.84)	1	–	0.82 (0.65–1.04)	2.50 (1.75–3.57)
β‐Blocker+diuretic	0.95 (0.59–1.55)	0.79 (0.49–1.25)	0.73 (0.44–1.21)	1.15 (0.70–1.93)	1	0.88 (0.73–1.06)	1.25 (1.01–1.55)
CCB	0.96 (0.76–1.22)	0.79 (0.61–1.01)	0.73 (0.56–0.95)	1.16 (0.89–1.54)	1.01 (0.63–1.60)	1
Diuretic	0.73 (0.57–0.92)	0.59 (0.45–0.76)	0.55 (0.41–0.73)	0.88 (0.67–1.14)	0.76 (0.45–1.25)	0.76 (0.58–0.98)	1

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

Values are expressed as odds ratios (ORs) and 95% credible intervals (CrIs) or confidence intervals (CIs). In the upper diagonal part, the OR (95% CI) compares the column condition with the row condition, and in the lower diagonal part, this OR (95% CrI) compares the column condition with the row condition.

Bold values indicate significance.